Literature DB >> 26555434

Prevalence of pain-related single nucleotide polymorphisms in patients of African origin with sickle cell disease.

Ellie H Jhun1, Yingwei Yao2,3, Ying He1, A Kyle Mack4, Diana J Wilkie2,3, Robert E Molokie1, Zaijie Jim Wang1.   

Abstract

BACKGROUND: Prospective pain genetics research is hindered by a lack of data on the prevalence of polymorphisms in pain-relevant genes for patients with sickle cell disease (SCD). For African-Americans in general, limited information is available in public databases.
METHODS: We prioritized and examined the genotype and allele frequencies of 115 SNPs from 49 candidate pain genes in 199 adult African-Americans and pediatric patients of African origin with SCD. Analyses were performed and compared with available data from public databases.
RESULTS: Genotype and allele frequencies of a number of SNPs were found to be different between our cohort and those from the databases and between adult and pediatric subjects.
CONCLUSION: As pain therapy is inadequate in a significant percentage of patients with SCD, candidate pain genetic studies may aid in designing precision pain medicine. We provide prevalence data as a reference for prospective genetic studies in this population.

Entities:  

Keywords:  African–American; SNPs; genotype; pain; pharmacogenomics; polymorphisms; population; sickle cell disease

Mesh:

Year:  2015        PMID: 26555434      PMCID: PMC4909047          DOI: 10.2217/pgs.15.126

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  34 in total

1.  Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients.

Authors:  Philippe Joly; Marie-Claude Gagnieu; Claire Bardel; Alain Francina; Corinne Pondarre; Cyril Martin
Journal:  Am J Hematol       Date:  2012-03-19       Impact factor: 10.047

2.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

3.  Outpatient pain predicts subsequent one-year acute health care utilization among adults with sickle cell disease.

Authors:  Miriam O Ezenwa; Robert E Molokie; Zaijie Jim Wang; Yingwei Yao; Marie L Suarez; Veronica Angulo; Diana J Wilkie
Journal:  J Pain Symptom Manage       Date:  2014-03-15       Impact factor: 3.612

Review 4.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

5.  Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease.

Authors:  Diana J Wilkie; Robert Molokie; Debra Boyd-Seal; Marie L Suarez; Young Ok Kim; Shiping Zong; Harriet Wittert; Zhongsheng Zhao; Yogen Saunthararajah; Zaijie J Wang
Journal:  J Natl Med Assoc       Date:  2010-01       Impact factor: 1.798

6.  Mu opioid receptor gene variants: lack of association with alcohol dependence.

Authors:  A W Bergen; J Kokoszka; R Peterson; J C Long; M Virkkunen; M Linnoila; D Goldman
Journal:  Mol Psychiatry       Date:  1997 Oct-Nov       Impact factor: 15.992

Review 7.  Role of central dopamine in pain and analgesia.

Authors:  Patrick B Wood
Journal:  Expert Rev Neurother       Date:  2008-05       Impact factor: 4.618

Review 8.  Common pathways of depression and pain.

Authors:  Pedro L Delgado
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

Review 9.  Targeting TRP channels for pain relief.

Authors:  Jill-Desiree Brederson; Philip R Kym; Arpad Szallasi
Journal:  Eur J Pharmacol       Date:  2013-03-14       Impact factor: 4.432

10.  Preliminary evidence for association between schizophrenia and polymorphisms in the regulatory Regions of the ADRA2A, DRD3 and SNAP-25 Genes.

Authors:  Jan Lochman; Vladimir J Balcar; František Sťastný; Omar Serý
Journal:  Psychiatry Res       Date:  2012-08-30       Impact factor: 3.222

View more
  7 in total

1.  Clinical and genetic factors are associated with pain and hospitalisation rates in sickle cell anaemia in Cameroon.

Authors:  Ambroise Wonkam; Khuthala Mnika; Valentina J Ngo Bitoungui; Bernard Chetcha Chemegni; Emile R Chimusa; Collet Dandara; Andre P Kengne
Journal:  Br J Haematol       Date:  2017-12-03       Impact factor: 6.998

Review 2.  An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.

Authors:  Khuthala Mnika; Gift D Pule; Collet Dandara; Ambroise Wonkam
Journal:  OMICS       Date:  2016-09-16

Review 3.  Pharmacogenomics of sickle cell disease: steps toward personalized medicine.

Authors:  Marium Husain; Amber D Hartman; Payal Desai
Journal:  Pharmgenomics Pers Med       Date:  2017-10-19

4.  Next-generation sequencing of the human TRPV1 gene and the regulating co-players LTB4R and LTB4R2 based on a custom AmpliSeq™ panel.

Authors:  Dario Kringel; Marco Sisignano; Sebastian Zinn; Jörn Lötsch
Journal:  PLoS One       Date:  2017-06-28       Impact factor: 3.240

5.  Genetic variants of GCH1 associate with chronic and acute crisis pain in African Americans with sickle cell disease.

Authors:  Nilanjana Sadhu; Ellie H Jhun; Yingwei Yao; Ying He; Robert E Molokie; Diana J Wilkie; Zaijie Jim Wang
Journal:  Exp Hematol       Date:  2018-07-19       Impact factor: 3.084

6.  Development of an AmpliSeqTM Panel for Next-Generation Sequencing of a Set of Genetic Predictors of Persisting Pain.

Authors:  Dario Kringel; Mari A Kaunisto; Catharina Lippmann; Eija Kalso; Jörn Lötsch
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

7.  Vasopressin SNP pain factors and stress in sickle cell disease.

Authors:  Keesha L Powell-Roach; Yingwei Yao; Ellie H Jhun; Ying He; Marie L Suarez; Miriam O Ezenwa; Robert E Molokie; Zaijie Jim Wang; Diana J Wilkie
Journal:  PLoS One       Date:  2019-11-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.